Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis.
OBJECTIVE
To compare the anticoagulation efficacy and clinical safety of domestically manufactured and imported low-molecular-weight-heparin during hemodialysis.


METHODS
Sixty patients on hemodialysis were randomly divided into 2 groups, who received intravascular injections of domestically manufactured or imported low-molecular-weight heparin to prevent coagulation. Active partial thromboplastin time (aPTT), prothrombin time (PT), thrombin time (TT) and factor Xa activity were determined during dialysis.


RESULTS
No incidence of major bleeding was encountered in all of these patients. Similarly low incidences of clotting in extracorporeal circuit were found in either group. No significant differences in aPTT, PT, TT and plasma levels of factor Xa were observed between the two groups.


CONCLUSIONS
Low-molecular-weight heparin domestically manufactured is safe and efficient for anticoagulation during hemodialysis as compared with the imported heparin.
Liu
Zhi-Qiang
ZQ
Department of Nephrology, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China.
Wang
Li
L
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D003257:Consumer Product Safety; D015951:Factor Xa; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D011517:Prothrombin Time; D006435:Renal Dialysis; D013918:Thrombin Time
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D015951:Factor Xa